The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with Braftovi (encorafenib) in combination with Erbitux (cetuximab) and chemotherapy, Guardant Health, Inc. announced in a news release.

Deaths from colorectal (bowel) cancer are increasing in people under 50s in the US, the only one of five leading cancers to do so, an analysis suggests.1 Researchers from the American Cancer Society (ACS) examined changes in cancer mortality in the US between 1990 and 2023,

A man was given two years to live after a colon cancer diagnosis. Now he's healthy thanks to combination of medicine and the right care team.

Fewer people under age 50 are dying from cancer in the U.S., but colorectal cancer mortality rates continue to surge